Yixin Cheng

Yixin Cheng

Auto-generated profile, based on publicly available information

Yixin Cheng

Sun Yat-sen University Cancer Center 6 Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
YCYixin Cheng
Yixin Cheng
PZPengkun Zhang
Pengkun Zhang
YHYulin Huang
Yulin Huang
ZZZhihui Zhang
Zhihui Zhang
RTRu Tang
Ru Tang
ZHZhen-Yu He
Zhen-Yu He
Objectives The present study aimed to develop and validate nomograms to predict the survival of patients with breast invasive micropapillary carcinoma (IMPC) to aid objective decision-making. Design Prognostic factors were identified using Cox proportional hazards regression analyses and used to construct nomograms to predict overall survival (OS) and breast cancer-specific survival (BCSS) at 3 and 5 years. Kaplan-Meier analysis, calibration curves, the area under the curve (AUC) and the concordance index (C-index) evaluated the nomograms’ performance. Decision curve analysis (DCA), integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were used to compare the nomograms with the American Joint Committee on Cancer (AJCC) staging system. Setting Patient data were collected from the Surveillance, Epidemiology, and End Results (SEER) database. This database holds data related to the incidence of cancer acquired from 18 population-based cancer registries in the US. Participants We ruled out 1893 patients and allowed the incorporation of 1340 patients into the present study. Results The C-index of the AJCC8 stage was lower than that of the OS nomogram (0.670 vs 0.766) and the OS nomograms had higher AUCs than the AJCC8 stage (3 years: 0.839 vs 0.735, 5 years: 0.787 vs 0.658). On calibration plots, the predicted and actual outcomes agreed well, and DCA revealed that the nomograms had better clinical utility compared with the conventional prognosis tool. In the training cohort, the NRI for OS was 0.227, and for BCSS was 0.182, while the IDI for OS was 0.070, and for BCSS was 0.078 (both p<0.001), confirming its accuracy. The Kaplan-Meier curves for nomogram-based risk stratification showed significant differences (p<0.001). Conclusions The nomograms showed excellent discrimination and clinical utility to predict OS and BCSS at 3 and 5 years, and could identify high-risk patients, thus providing IMPC patients with personalised treatment strategies.

4 December 2025 in Cancer Research
Verified
Journal Article
Closed access
YCYixin Cheng
Yixin Cheng
GHGuanyin Huang
Guanyin Huang
XLXuefei Liu
Xuefei Liu
CWChun Wu
Chun Wu
JLJingru Lian
Jingru Lian
XHXIN HONG
XIN HONG
Intratumoral heterogeneity supports cancer progression and metastasis while limiting therapeutic efficacy. Comprehensive biological characterization of heterogeneous subclones in breast cancer may hold promise in battling against this deadly disease. Using single-cell transcriptomic analysis and in situ profiling of primary tumors, metastases, and circulating tumor cells from multiple patients with breast cancer, we identified a unique EPCAM+ CD68+ TREM2+ tumor subpopulation, likely resulting from the fusion of tumor cells and lipid-associated macrophages (LAM). The presence of these tumor–LAM fusion cells in the blood or in distinct metastatic sites was significantly correlated with metastatic progression. Stable fusion clonal lines established in vitro exhibited substantially enhanced proliferation, tumor initiation, and metastasis formation in mice. Integrative molecular and functional analyses revealed a critical role for SNX10 in mediating tumor–LAM fusion. Mechanistically, SNX10 physically interacted with the phospholipid scramblase ANO6 and maintained its protein stability by suppressing proteasome-mediated degradation. Furthermore, the transcription factor CBX3 directly targeted SNX10 promoter and modulated its expression. Fusion cells accumulated abundant intracellular lipid droplets and were highly sensitive to simvastatin treatment in vitro and in vivo. Together, this study uncovered that CBX3–SNX10–ANO6 signaling facilitates generation of an aggressive tumor-LAM fusion cell subpopulation that promotes metastasis, revealing an alternative metastatic mechanism and exposing putative therapeutic vulnerabilities. Significance: Single-cell transcriptomic profiling combined with functional and clinical validation identifies fusion of tumor cells and lipid-associated macrophages mediated by the CBX3–SNX10–ANO6 axis as a potentially targetable mechanism driving cancer metastasis.

8 June 2026 in Cancer Discovery
Verified
Journal Article
Closed access
XLXuefei Liu
Xuefei Liu
JTJun Tan
Jun Tan
CWChun Wu
Chun Wu
GHGuanyin Huang
Guanyin Huang
YCYixin Cheng
Yixin Cheng
XHXIN HONG
XIN HONG
Brain metastasis remains a devastating disease with dismal prognosis. How circulating tumor cells (CTC) penetrate the blood–brain barrier (BBB) and reprogram the brain microenvironment remains unclear. Using spatially resolved multi-omics profiling of CTCs and brain metastases, integrated with experimental and clinical analyses, we identified glycoprotein nonmetastatic melanoma protein B (GPNMB) as a CTC-secreted driver of vascular disruption and brain colonization. CBX3 upregulation induced GPNMB expression, which bound endothelial EGFR, triggering CBL-mediated ubiquitination and degradation. Attenuated EGFR signaling suppressed FTO and disrupted endothelial junctions via YTHDF2-dependent TJP1 m6A methylation. Remarkably, GPNMB-induced BBB remodeling promoted immune infiltration via the CXCL12–CXCR4 axis and induced time-course–dependent T-cell exhaustion within the brain microenvironment. Clinically, elevated CBX3+GPNMB+ CTCs and plasma CXCL12 were significantly associated with brain metastasis progression in lung cancer and melanoma. Therapeutically, dual blockade of GPNMB and PD1 enhanced anti–brain metastasis efficacy in mice, unveiling GPNMB as a promising target for precision immunotherapy. Significance: GPNMB is a CTC-secreted driver of BBB disruption and brain colonization via the CBX3-GPNMB–EGFR–FTO–TJP1 axis. GPNMB-induced BBB remodeling promotes CXCL12–CXCR4-mediated immune infiltration and enhances T-cell exhaustion, sensitizing brain metastasis tumors to GPNMB/PD1 dual blockade. CBX3+GPNMB+ CTCs and plasma CXCL12 may serve as noninvasive biomarkers for brain metastasis management.

2 July 2026
Verified
Other
Open access
MYMingke Yu
Mingke Yu
LDLianhui Duan
Lianhui Duan
YHYulin Huang
Yulin Huang
YCYixin Cheng
Yixin Cheng
YWYuting Wang
Yuting Wang
XLXuefei Liu
Xuefei Liu
Supplementary Table S2 from NMB+CXCL13+CD4+ T Cell–Derived Neuromedin B Promotes Neuropeptide S Receptor 1–Positive Malignant Cell Senescence and Malignancy

2 July 2026
Verified
Other
Open access
MYMingke Yu
Mingke Yu
LDLianhui Duan
Lianhui Duan
YHYulin Huang
Yulin Huang
YCYixin Cheng
Yixin Cheng
YWYuting Wang
Yuting Wang
XLXuefei Liu
Xuefei Liu
Supplementary Figure S3. Comprehensive characterization of CD8+ T cell subsets in CRC.

2 July 2026
Verified
Other
Open access
MYMingke Yu
Mingke Yu
LDLianhui Duan
Lianhui Duan
YHYulin Huang
Yulin Huang
YCYixin Cheng
Yixin Cheng
YWYuting Wang
Yuting Wang
XLXuefei Liu
Xuefei Liu
The differentially expressed genes in Epi_NPSR1 subcluster.